Targeting pain in Parkinson's disease

Treatment with OXN PR had no effect on patient motor function as measured with the Unified Parkinson's Disease Rating Scale part III, whereas severe pain improved, supporting the use of drugs targeting receptors like opioid in addition to the dopamine system.8 Dopaminergic drugs are efficacious...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2015-12, Vol.14 (12), p.1144-1145
Main Authors: Antonini, Angelo, Tinazzi, Michele
Format: Article
Language:English
Subjects:
Analgesics, Opioid - therapeutic use
Dopamine
Drug dosages
Female
Humans
Male
Naloxone - therapeutic use
Neurology
Oxycodone - therapeutic use
Pain - drug therapy
Parkinson Disease - complications
Parkinson's disease
Quality of life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment with OXN PR had no effect on patient motor function as measured with the Unified Parkinson's Disease Rating Scale part III, whereas severe pain improved, supporting the use of drugs targeting receptors like opioid in addition to the dopamine system.8 Dopaminergic drugs are efficacious for other non-motor symptoms such as mood and sleep disorders, supporting the idea that these symptoms are related to dopaminergic denervation in regions of the brain not primarily linked to motor disability.9,10 Finally, a study11 of patients with Parkinson's disease and high degree of overall non-motor disability including prominent pain failed to show superiority of the dopamine agonist rotigotine compared with placebo, confirming that the mechanisms of non-motor symptoms are heterogeneous.
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(15)00286-0